JP2017509628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509628A5 JP2017509628A5 JP2016556898A JP2016556898A JP2017509628A5 JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5 JP 2016556898 A JP2016556898 A JP 2016556898A JP 2016556898 A JP2016556898 A JP 2016556898A JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- insr
- disorder
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims 11
- 102100036721 Insulin receptor Human genes 0.000 claims 11
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 5
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 3
- 102000003746 Insulin Receptor Human genes 0.000 claims 3
- 108010001127 Insulin Receptor Proteins 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 102000056713 human FGF21 Human genes 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 206010053857 partial lipodystrophy Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950960P | 2014-03-11 | 2014-03-11 | |
| US61/950,960 | 2014-03-11 | ||
| PCT/US2015/019362 WO2015138278A1 (en) | 2014-03-11 | 2015-03-09 | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020094831A Division JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509628A JP2017509628A (ja) | 2017-04-06 |
| JP2017509628A5 true JP2017509628A5 (enExample) | 2018-04-05 |
| JP6712230B2 JP6712230B2 (ja) | 2020-06-17 |
Family
ID=52682963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556898A Active JP6712230B2 (ja) | 2014-03-11 | 2015-03-09 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| JP2020094831A Pending JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020094831A Pending JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170065678A1 (enExample) |
| EP (1) | EP3125921B1 (enExample) |
| JP (2) | JP6712230B2 (enExample) |
| WO (1) | WO2015138278A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| EP3649157A4 (en) * | 2017-07-06 | 2021-07-28 | Yale University | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO ENDOCRINE FGF |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU2003236557B2 (en) * | 2002-06-27 | 2009-10-01 | Verva Pharmaceuticals Pty Ltd | Differentiation modulating agents and uses therefor |
| ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| CA2544602A1 (en) * | 2003-11-04 | 2005-05-26 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CA2549249A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| BRPI0507302A (pt) * | 2004-01-29 | 2007-06-26 | Applied Research Systems | método e composições para o tratamento da lipodistrofia |
| US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| EP2185178B1 (en) | 2007-08-03 | 2017-08-23 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EP2358749B1 (en) | 2008-10-10 | 2018-07-18 | Amgen, Inc | Fgf21 mutants and uses thereof |
| CN102361647B (zh) | 2009-01-23 | 2018-02-16 | 诺沃-诺迪斯克有限公司 | 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用 |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
| WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| KR101952453B1 (ko) | 2009-10-15 | 2019-02-26 | 제넨테크, 인크. | 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자 |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2460527A1 (en) | 2010-01-21 | 2012-06-06 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| ES2543634T3 (es) | 2010-01-22 | 2015-08-20 | Novo Nordisk A/S | Proceso para preparación de FGF-21 con grado de O-glicosilación bajo |
| JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質 |
| US9655974B2 (en) | 2010-07-20 | 2017-05-23 | Novo Nordisk A/S | N-terminal modified FGF21 compounds |
| CA2885176C (en) | 2010-09-22 | 2018-10-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| RU2013118441A (ru) | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| EP2392927A1 (en) * | 2011-03-11 | 2011-12-07 | F. Hoffmann-La Roche AG | Diagnosis of metabolic disorders in HIV infected patients |
| EP2723391B1 (en) | 2011-06-24 | 2018-06-13 | University of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| EP2750695A2 (en) * | 2011-08-31 | 2014-07-09 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| TWI593708B (zh) * | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| TW201420606A (zh) | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
| JP2015533483A (ja) | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
| WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016048999A2 (en) | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
-
2015
- 2015-03-09 WO PCT/US2015/019362 patent/WO2015138278A1/en not_active Ceased
- 2015-03-09 EP EP15710087.6A patent/EP3125921B1/en active Active
- 2015-03-09 US US15/124,877 patent/US20170065678A1/en not_active Abandoned
- 2015-03-09 JP JP2016556898A patent/JP6712230B2/ja active Active
-
2019
- 2019-05-09 US US16/407,813 patent/US11963999B2/en active Active
-
2020
- 2020-05-29 JP JP2020094831A patent/JP2020147583A/ja active Pending
-
2024
- 2024-03-19 US US18/609,420 patent/US20240293508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509628A5 (enExample) | ||
| GT201600263A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
| JP6379300B2 (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| HRP20211575T1 (hr) | Fuzijski proteini za liječenje metaboličkih poremećaja | |
| Hassan et al. | Evolution and clinical translation of drug delivery nanomaterials | |
| CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
| JP2014526441A5 (enExample) | ||
| BR112018008805A8 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
| WO2013009545A8 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2014500880A5 (enExample) | ||
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| AR083920A1 (es) | Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21) | |
| EP4306165A3 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| JP2014530220A5 (enExample) | ||
| JP2016503770A5 (enExample) | ||
| FI3452507T3 (fi) | Tau-immuunihoito | |
| JP2017512194A5 (enExample) | ||
| BR112013030067A2 (pt) | "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" | |
| WO2016109823A8 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| JP2017507142A5 (enExample) | ||
| RU2010113994A (ru) | Применение панкреатического полипептида человека в качестве терапевтического средства | |
| JP2010500284A5 (enExample) | ||
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| Maksimov et al. | Possibilities of placentary medicine in restoration treatment | |
| RU2017137262A (ru) | Применение (4-гидрокси-2-метил-1,1-диоксид-2н-бензо[е][1,2]тиазин-3-ил)(нафталин-2-ил)метанона для профилактики и/или лечения неалкогольного стеатогепатита |